fpi-2265
fpi-2265: sourced relationships with 1 company · 3 clinical trials tracked.
fpi-2265 evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could fpi-2265 → FUSN affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Fusion Pharmaceuticals Inc. (FUSN) Metastatic Castration-resistant Prostate Cancer; Metastatic … | Phase 2 |
Clinical Trial Registry Records (3)
A Phase 2, Open-label, Multi-centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Primary endpoint: Evaluate anti-tumour activity of FPI-2265 administered in combination with olaparib
A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of FPI-2265 (225Ac-PSMA-I&T) in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Primary endpoint: Frequency, duration, and severity of treatment-emergent adverse events (TEAEs)
PSMA-directed Targeted Alpha Therapy With FPI-2265 (225Ac-PSMA-I&T) for the Treatment of Metastatic Castration-resISTant Prostate Cancer (TATCIST). A Phase II Clinical Trial.
Primary endpoint: To evaluate the effect of FPI-2265 on prostate-specific antigen (PSA) in participants with mCRPC.
Frequently asked questions
Which companies have sourced relationships with fpi-2265?
fpi-2265 has dated SEC/FDA relationship records for Fusion Pharmaceuticals Inc..
How many clinical trials involve fpi-2265?
BioSniper tracks 3 clinical trials involving fpi-2265.